Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10768965 | 0.82 | POLB (0.52) | POLBKDM4EL3MBTL1DRD1DRD4 | |
| SCHEMBL24731308 | 0.81 | DRD1 (0.61) | POLBKDM4EDRD1DRD4DRD5 | |
| SCHEMBL14027686 | 0.81 | ALDH1A1 (0.54) | POLBALDH1A1TDP1 | |
| SCHEMBL1854474 | 0.81 | POLB (0.56) | POLBKDM4EL3MBTL1DRD1DRD4 | |
| SCHEMBL6042440 | 0.80 | POLB (0.68) | POLBKDM4EL3MBTL1DRD1DRD4 | |
| SCHEMBL5412929 | 0.79 | MEN1 (0.55) | POLBKDM4EMEN1KMT2A | |
| SCHEMBL12764922 | 0.78 | DRD1 (0.54) | POLBKDM4EDRD1DRD4DRD5 | |
| SCHEMBL6689247 | 0.78 | DRD1 (0.68) | POLBKDM4EL3MBTL1DRD1DRD4 | |
| SCHEMBL6044278 | 0.77 | MEN1 (0.72) | POLBKDM4EL3MBTL1DRD1DRD4 | |
| SCHEMBL240294 | 0.77 | DRD1 (0.71) | POLBKDM4EL3MBTL1DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | POLB 2314/4885KDM4E 2802/4885L3MBTL1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.